Consilium supports Euronext listing of innovative medical device company
London, 28 March 2019, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is delighted to have advised on the successful IPO of Sequana Medical NV which has listed on Euronext Brussels raising EUR 27.5 million. Sequana Medical is now trading on Euronext Brussels under the symbol “SEQUA”.
The Consilium Strategic Communications team comprising Amber Fennell, Alexandra Harrison, Sukaina Virji, Melissa Gardiner (London) and Marieke Vermeersch (Belgium), will continue to advise the Company on its financial communications and investor relations as a publicly listed company.
Sequana Medical is a commercial stage medical device company focused on the development of
innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders.
“Sequana Medical is a highly innovative medical device company addressing one of the world’s fastest growing health threats caused by unhealthy lifestyles. We are delighted to have supported such a future-minded company and to have advised the team on the successful IPO. We are enjoying our ongoing relationship with the Sequana team as it operates as a public company.”
Amber Fennell
Partner and Co-Founder of Consilium Strategic Communications
“Consilium has been a trusted advisor for us throughout the IPO process, helping us craft our message to demonstrate the investment rationale of Sequana Medical and our alfapump® and alfapump® DSR technologies. The team has worked with us to great effect and through its influence with the media, we have successfully reached our target audiences.”
Ian Crosbie
Chief Executive Officer of Sequana Medical
